| 略語 | ||
| 通常英語（アルファベット略名など）で用いられる用語 | ||
| 【A】 | ADA欠損症 | Adenosine deaminase deficiency |
| ADME | ||
| ARR | Absolute Risk Reduction 絶対リスク減少率 | |
| 【B】 | BMI | Body Mass Index |
| BNP | Brain Natriuretic Peptide | |
| 【C】 | COMT阻害薬 | Catechol-ο-Methyl Transferase inhibitor |
| COX2選択的阻害薬 | Cyclooxygenase-2 Selective Inhibitor | |
| CR | Complete Remission(Response) 完全寛解 | |
| CRO | Contract Research Organization | |
| CT | Computed Tomographyコンピュータ断層撮影法 | |
| CTL療法 | Cytolytic T Lymphocytes | |
| 【D】 | DBT | Double Blind Test 二重盲検法 |
| DEM | Drug Event Monitoring 薬剤イベントモニタリング | |
| DIC syndrome | Disseminated Intravascular Coagulation syndrome 播種性血管内凝固症候群 | |
| Dipper／Non-Dipper | ||
| DMARD | Disease Modifying Antirheumatic Drug | |
| DSU | Drug Safety Update 医薬品安全対策情報 | |
| 【E】 | EBM | Evidence Based Medicine |
| ED | Erectile Dysfunction 勃起不全または勃起障害 | |
| EPR効果 | Enhanced Permeability and Retention effect | |
| 【F】 | FDA | Food and Drug Administration 米国食品医薬品局 |
| FIC Index | Fractional Inhibitory Concentration index | |
| 【G】 | GCP | Good Clinical Practice |
| G-I 療法 | Glucagon-Insulin therapy | |
| GSP | Good Supplying Practice | |
| GMP | Good Manufacturing Practice | |
| GLP | Good Laboratory Practice | |
| GPSP | Good Promotional and Supplying Practice | |
| GPMSP | Good Post－Marketing Surveillance Practice | |
| GPP | Good Practices in Pharmacy | |
| GUP | Good Using Practice | |
| 【H】 | H2受容体拮抗薬 | H2-Bloker |
| HGF | hepatocyte growth factor | |
| HMG-CoA還元酵素阻害薬 | HMG-CoA reductase enzyme inhibitor | |
| HLA | Human Leukocyte Antigen | |
| HPN | Home Parenteral Nutrition 在宅中心静脈栄養 | |
| 【I】 | ICH | International Conference on Harmonisation |
| ICU syndrome | Intensive Care Unit syndrome | |
| 【J】 | JANコード | Japanese Article Number |
| 【L】 | LAK療法 | Lymphokine Activated Killer |
| 【M】 | MAO阻害薬 | Monoamine Oxidase Inhibitor |
| MDRP | Multidrug resistant Pseudomonas 多剤耐性緑膿菌 | |
| Med DRA／J | Medical Dictionary for Regulatory Activities／J | |
| MIC | Minimum Inhibitory Concentration 最小発育阻止濃度 | |
| MR | Medical Representatives 製薬会社の医療情報担当者 | |
| MR認定試験 | ||
| MRI | Magnetic Resonance Imaging 磁気共鳴映像法 | |
| MS | Marketing Specialists 医薬品卸売業の営業担当者 | |
| 【N】 | NMDA受容体拮抗薬 | N-Metyl-D-Asparatic acid receptor antagonist |
| NNT | Number Needed to Treat | |
| NST | Non-Stress Test | |
| NUD | Non Ulcer Dyspepsia | |
| 【O】 | O-157 | |
| 【P】 | P-糖タンパク質 | P-glycoprotein |
| P-450 | ||
| PAE | Post Antibiotic Effect 抗生物質有効濃度後効果 | |
| PDT | Photodynamic Therapy 光線力学的療法 | |
| P-drug | Personal drug | |
| PEIT | Percutaneous Ethanol Injection Therapy 経皮的エタノール注入療法 | |
| PEM | Prescription Event Monitoring 処方イベントモニタリング | |
| PL法 | Product Liability 製造物責任法 | |
| PMS | Post Marketing Surveilance 市販後調査 | |
| POMR | Problem Oriented Medical Record | |
| POS | Problem Oriented System 問題志向型システム | |
| PPAR | Peroxisome Proliferator Activated Receptor | |
| PR | Partial Remission（Response) 部分寛解 | |
| PRSP | Penicillin Resistant Streptococcus Pneumoniae ペニシリン耐性肺炎球菌 | |
| PTSD | Post-Traumatic Stress Disorder 心的外傷後ストレス障害 | |
| 【Q】 | QA | Quality Assurance 品質保証 |
| QC | Quality Control 品質管理 | |
| QOL | Quality of Life | |
| QT延長 | ||
| 【R】 | RRR | Relative Risk Reduction 相対リスク減少率 |
| 【S】 | SBA | サマリーベーシス・オブ・アプルーバル Sammary Basis of Approval |
| SBR | Summary Basis of Reexamination 再審査結果概要 | |
| SNRI | Serotonin-Noradrenarine Reuptake Inhibitor | |
| SOAP | ||
| SOP | Standard Operating Procedures 標準業務手順書 | |
| SSRI | Selective Serotonin Reuptake Inhibitor 選択的セロトニン再取り込み阻害薬 | |
| 【T】 | Tdp | Torsades de pointe(トルサード・ド・ポアント／仏) |
| T／P比 | Trough／Peak | |
| TPN | Total Parenteral Nutrition 中心静脈栄養法 | |
